Scientific Abstracts
1 baricitinib provided significant improvement in pain reduction. It is not clear, however, how much reductions in pain impacted other aspects of life, such as work productivity. Objectives: To assess the relationship between pain reduction and improvements, regardless of treatment, in daily activity and work productivity in patients with RA. Methods: In this post-hoc analysis of RA-BEAM 1 , pain for the intention-to-treat patients was assessed using the patient's assessment of pain (0-100 mm visual analogue scale). The Work Productivity and Activity Impairment Questionnaire-RA (WPAI-RA) instrument was used to evaluate the percentage of activity impairment due to RA (impairment in regular daily activities, N=1302), percentage of work-time missed due to RA (absenteeism, N=521), percentage of impairment while working due to RA (presenteeism, N=490), and percentage of overall work impairment due to RA (impairment in work productivity, N=490). Pain was divided into pain reduction groups (<30%, 30% − <50%, ≥50% at Weeks 12 and 24; ≥30% [Y/N] and ≥50% [Y/N] at Weeks 1 and 2). Pairwise comparisons on improvement in WPAI-RA scores between pain reduction groups at Weeks 12 and 24 were assessed by ANCOVA adjusting for region, baseline joint erosion status, and baseline values of outcome variables. Missing values were imputed using the modified last-observation carried forward method. Results: At baseline across treatment groups, the mean values ranged from 56-58 for daily activity impairment, 12-13 for absenteeism, 42-46 for presenteeism, and 45-49 for work productivity impairment. A ≥30% reduction in pain as early as Week 1 was associated with significantly greater (p<0.001) improvement than <30% pain reduction in regular daily activity (-22.8 vs -16.0), presenteeism (-17.5 vs. -12.1) , and work productivity (-16.8 vs. -11.6 ) at Week 12. Greater improvement was observed in most WPAI-RA scores in patients who had more pain reduction at Weeks 12 and 24; with a reduction of ≥50% in pain from baseline, the WPAI-RA scores were substantially improved at Weeks 12 or 24 for daily activity, presenteeism, and work productivity (Table) .
Conclusions:
Regardless of treatment, pain reduction was associated with improved regular daily activity and work productivity in patients with RA, with larger levels of reduction related to more improvement. 
Methods:
We evaluated the MBDA test in patients from one of the sites participating in the Solna Epidemiological Investigation of RA (EIRA) cohort. EIRA patients were eligible if they were ≥18 years; RA diagnosis within 12 months of symptom duration; had serum and clinical assessments at BL and M3; and clinical follow-up data in the Swedish Rheumatology Quality Register. Patients naïve to disease modifying anti-rheumatic drugs who received MTX were included. Kruskal-Wallis was used to test the null hypothesis that medians of MBDA scores of 3 EULAR response groups are equal. Receiver operating characteristic (ROC) analysis was performed. The optimal threshold of MBDA associated with DAS28-ESR improvement (decrease in DAS-ESR >1.2 at M3) was determined by Youden criterion maximizing sum of sensitivity and specificity. Results: 176 patients were included: 72% women, mean age 51 (SD: 11.7) years, mean DAS28-ESR score 5.6 (SD: 0.99); 51% had ESR <28 mm/hr, 66% were anti-CCP2+, and 22% received prednisone. Mean BL MBDA score was 56.8 (SD: 14.7) with 8 (5%) patients in low (<30), 29 (16%) patients in moderate (30-44) and 139 (79%) patients in high MBDA disease activity categories. Median MBDA scores for patients with no EULAR response worsened by 2 points and for patients with moderate and good response improved by 12 and 16 points, respectively (p<0.0001 across groups, Fig 1A) . Median MBDA scores improved by 10 points for all patients and 15 points in patients with a DAS28-ESR decrease >1.2. The best combination of sensitivity and specificity to achieve a DAS28-ESR decrease >1.2 was provided by a ≥8 point MBDA score improvement (Fig 1B) . A similar result was obtained using the bootstrap method. AUROC was 0.77 (95% CI: 0.71, 0.84). 125 patients (71%) had concordance between DAS28-ESR improvement and MBDA improvement at the optimal threshold (Table 1) . 
Conclusions:
The optimal threshold of MBDA score associated with a clinically relevant decrease of DAS28 was 8 points. Using this threshold, the MBDA test is informative to detect clinical improvement. Thus, based on these results improvement in MBDA score ≥8 points at M3 after initiating MTX is indicative of meaningful clinical improvement.
